GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. officer Roland Rott, CEO of Imaging, reported a routine tax-related share withholding. On February 1, 2026, 558 shares of common stock were withheld at $78.97 per share to cover tax obligations from vesting restricted stock units. After this transaction, Rott directly owned 28,564 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. GC & Corporate Secretary Frank R. Jimenez reported an automatic share withholding related to equity compensation. On February 1, 2026, 947 shares of common stock were withheld at $78.97 per share to cover tax obligations on vested restricted stock units. After this transaction, he directly beneficially owned 67,546 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc.’s Chief Financial Officer, James Saccaro, reported a routine tax‑related share withholding. On February 1, 2026, 948 shares of common stock were withheld at $78.97 per share to cover tax obligations from vesting restricted stock units. After this transaction, Saccaro beneficially owned 57,646 shares of GE HealthCare Technologies common stock, held directly.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini had 3,210 shares of common stock withheld on February 1, 2026 to cover taxes on vesting restricted stock units. The shares were valued at $78.97 each for this tax withholding event.
After this transaction, Arduini directly beneficially owned 164,672 shares of GE HealthCare Technologies Inc. common stock. This was a tax-related share withholding by the company rather than an open-market sale.
GE HealthCare Technologies Inc. arranged new debt financing to support its acquisition of Intelerad Medical Systems. The company entered into a three-year senior unsecured term loan credit facility that provides a committed $750 million term loan, to be drawn in a single borrowing on a later date once customary conditions are met and repaid in full on the third anniversary of funding. Interest can be based on either an alternate base rate or term SOFR for selected interest periods, with a margin tied to the company’s senior unsecured long-term debt ratings.
The credit agreement includes customary covenants limiting liens, certain fundamental transactions, leverage levels, and subsidiary indebtedness, along with standard events of default such as missed payments, covenant breaches, cross-acceleration of other material debt, bankruptcy events, material judgments, and change of control. Separately, GE HealthCare issued $600 million of 4.150% senior notes due December 15, 2028 and $650 million of 4.950% senior notes due December 15, 2035 under an effective shelf registration. The company plans to use the net proceeds from these notes, together with the term loan and cash on hand, to pay the purchase price of the Intelerad acquisition.
GE HealthCare Technologies reported third‑quarter results reflecting steady growth. Total revenues were $5,143 million, up from $4,863 million a year ago, driven by higher product sales and services. Net income attributable to GE HealthCare was $446 million versus $470 million, and diluted EPS was $0.98 compared with $1.02. Operating income was $653 million, modestly below $676 million last year, as higher cost of products offset revenue gains.
For the first nine months, revenues reached $14,927 million and diluted EPS was $3.26. Cash from operating activities was $937 million. The company closed the acquisition of the remaining 50% of Nihon Medi‑Physics for $271 million cash consideration and recognized a $97 million remeasurement gain. It also issued $650 million 4.800% notes due 2031 and $850 million 5.500% notes due 2035. Cash and equivalents were $4,027 million, and total principal debt was $10,275 million. RPO was $15,096 million, indicating future revenue under contract. The company repurchased $200 million of stock year‑to‑date and declared dividends of $0.105 per share. Shares outstanding were 455,521,592 as of October 22, 2025.
GE HealthCare Technologies Inc. (GEHC) furnished its third quarter 2025 financial results press release on an 8-K dated October 29, 2025. The press release is included as Exhibit 99.
The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference unless expressly stated. GE HealthCare’s common stock trades on Nasdaq under the symbol GEHC.
Form 144 notice for GE HealthCare Technologies Inc. (GEHC) discloses a proposed sale of 19,524 common shares through UBS Financial Services on 09/22/2025 on NASDAQ with an aggregate market value of $1,453,773. The filing lists the outstanding share count as 456,562,037. The shares were acquired through restricted stock vesting in four tranches between 09/01/2024 and 09/01/2025, totaling the listed units. The filer also reported a prior sale by Kenneth Stacherski of 11,757 shares on 09/12/2025 for gross proceeds of $905,590. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
GE HealthCare Technologies insider transaction: Kenneth R. Stacherski, Chief Enterprise Operating Officer, reported two disposals of GEHC common stock on 09/01/2025. The filings show 458 shares and 434 shares were disposed of at a price of $73.73 per share, resulting in 41,430 and 40,996 shares beneficially owned after each reported transaction.
The form states these disposals represent withholding of shares to satisfy tax withholding obligations in connection with the vesting of restricted stock units. The Form 4 was signed by the company’s General Counsel as attorney-in-fact on 09/03/2025.
Holton Adam Y, identified as an officer (Chief People Officer) of GE HealthCare Technologies Inc. (GEHC), reported a transaction dated 09/01/2025. The filing shows 464 shares of GEHC common stock were disposed of at a price of $73.73 per share under transaction code F. The report states these shares were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. After the withholding, the reporting person beneficially owned 16,768 shares. The Form 4 was signed by an attorney-in-fact, Frank R. Jimenez, on 09/03/2025.